
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV is demonstrating a commitment to advancing its pipeline of gene therapies, highlighted by strong data from ongoing Phase 1/2 studies of AMT-130 for Huntington's disease, which management asserts possesses an unprecedented efficacy and biomarker profile. Additionally, the company's recent positive reviews from an Independent Data Monitoring Committee (IDMC) signal encouraging progress in clinical trials, such as the GenTLE trial for mesial temporal lobe epilepsy, bolstering confidence in its developmental pathway. Furthermore, management’s assurance regarding the favorable risk-benefit profile of AMT-130, alongside the absence of new concerns from regulatory bodies, supports a positive outlook for uniQure’s future growth potential within the gene therapy sector.
Bears say
uniQure NV faces significant challenges that contribute to a negative outlook on its stock. The company has incurred losses since its inception and lacks a revenue-generating product, which raises financial risks, particularly given its status as a clinical-stage entity. Additionally, recent setbacks regarding AMT-130's regulatory approval process, combined with intensified market competition for similar therapies, may further hinder its ability to penetrate the market and achieve timely commercialization.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares